Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
Background This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. Methods A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assess...
Saved in:
| Published in: | British journal of surgery Vol. 104; no. 13; pp. 1816 - 1828 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Chichester, UK
John Wiley & Sons, Ltd
01.12.2017
Oxford University Press |
| Subjects: | |
| ISSN: | 0007-1323, 1365-2168, 1365-2168 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Methods
A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging.
Results
TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2; median overall survival (OS) not reached) and non‐responders (TRG 3–5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non‐responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001).
Conclusion
A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1–2. Among local non‐responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders.
Response associated with survival |
|---|---|
| AbstractList | BackgroundThis multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.MethodsA questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging.ResultsTRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2; median overall survival (OS) not reached) and non‐responders (TRG 3–5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non‐responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001).ConclusionA clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1–2. Among local non‐responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. Background This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. Methods A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging. Results TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1–2; median overall survival (OS) not reached) and non‐responders (TRG 3–5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non‐responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001). Conclusion A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1–2. Among local non‐responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. Response associated with survival This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.BACKGROUNDThis multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging.METHODSA questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging.TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1-2; median overall survival (OS) not reached) and non-responders (TRG 3-5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001).RESULTSTRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1-2; median overall survival (OS) not reached) and non-responders (TRG 3-5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001).A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1-2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders.CONCLUSIONA clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1-2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. Response associated with survival This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging. TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1-2; median overall survival (OS) not reached) and non-responders (TRG 3-5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001). A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1-2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders. |
| Author | Turkington, R. Bornschein, J. Taniere, P. Miremadi, A. Peters, C. Kaye, P. Suortamo, S. Edwards, P. A. W. Hayes, S. J. Skipworth, R. J. E. Safranek, P. MacRae, S. Save, V. Barr, H. Fitzgerald, R. C. Whiting, J. Parsons, S. L. Hupp, T. R. Byrne, J. Duffy, J. Mercer, S. Noorani, A. Tavaré, S. Hannah, G. Griffiths, E. Lynch, A. G. Bower, L. Ford, H. Puig, S. de la Rue, R. Owsley, J. Vohra, R. Scott, M. Secrier, M. Walker, R. Gilligan, D. Shepherd, N. Oakes, S. Davies, J. O'Neill, J. R. Zylstra, J. Cheong, E. Berrisford, R. Abdullahi, Z. Beardsmore, D. Lagergren, J. Nutzinger, B. Hardwick, R. Bedford, M. Chang, F. Grabowska, A. Ang, Y. Preston, S. R. Hindmarsh, A. Crawte, J. Bagwan, I. Sothi, S. Davies, A. McManus, D. Carroll, N. Crichton, C. Old, O. Kelly, J. O'Donovan, M. Lewis, M. Lloyd, M. A. Underwood, T. J. Sanders, G. Hayden, A. Gossage, J. Sutaria, R. Eldridge, M.D. Soomro, I. N. Contino, G. Kumar, B. Welch, I. Saunders, J. H. Fels Elliott, R. Haidry, R. Grehan, N. Lovat, L. Harden, C. Igali, L. Noble, F. Malhotra, S. Sujendran, V. Lishman, S. Bunting, D. Eneh, V. |
| AuthorAffiliation | Karolinska Institute , Stockholm, Sweden Norfolk and Norwich University Hospital NHS Foundation Trust , Norwich, UK University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK University Hospital Southampton NHS Foundation Trust , Southampton, UK Oesophago-Gastric Unit, Addenbrooke's Hospital , Cambridge, UK Nottingham University Hospitals NHS Trust , Nottingham, UK Edinburgh University , Edinburgh, UK University Hospitals Coventry and Warwickshire NHS Trust , Coventry, UK Department of Surgery, Portsmouth NHS Trust , Portsmouth, UK Cancer Research UK Cambridge Institute, University of Cambridge , Cambridge, UK Plymouth Hospitals NHS Trust , Plymouth, UK Imperial College , London, UK Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge , Cambridge, UK Department of Surgery, University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK Wythenshawe Hospital , Manchester, UK Department of Surgery, Royal Infirmary of Edinburgh |
| AuthorAffiliation_xml | – name: Salford Royal NHS Foundation Trust, Salford, Leigh NHS Foundation Trust , Wigan – name: St Thomas's Hospital and King's College London , London, UK – name: University College London , London, UK – name: Faculty of Medical and Human Sciences, University of Manchester , Manchester, UK – name: Norfolk and Waveney Cellular Pathology Network , Norwich, UK – name: Department of Histopathology, Cambridge University Hospital NHS Trust , Cambridge, UK – name: Oesophago-Gastric Unit, Addenbrooke's Hospital , Cambridge, UK – name: Plymouth Hospitals NHS Trust , Plymouth, UK – name: Gloucester Royal Hospital , Gloucester, UK – name: Cancer Research UK Cambridge Institute, University of Cambridge , Cambridge, UK – name: Oxford ComLab, University of Oxford , Oxford, UK – name: Department of Surgery, Portsmouth NHS Trust , Portsmouth, UK – name: Imperial College , London, UK – name: University Hospitals Coventry and Warwickshire NHS Trust , Coventry, UK – name: University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK – name: Nottingham University Hospitals NHS Trust , Nottingham, UK – name: Wythenshawe Hospital , Manchester, UK – name: Peterborough City Hospital, Peterborough Hospitals NHS Trust , Peterborough, UK – name: Edinburgh Royal Infirmary , Edinburgh, UK – name: Norfolk and Norwich University Hospital NHS Foundation Trust , Norwich, UK – name: Centre for Cancer Research and Cell Biology, Queen's University Belfast , Belfast, UK – name: Royal Surrey County Hospital NHS Foundation Trust , Guildford, UK – name: Hutchison/Medical Research Council Cancer Unit, University of Cambridge , Cambridge, UK – name: Edinburgh University , Edinburgh, UK – name: Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK – name: Cancer Sciences Unit, University of Southampton , Southampton, UK – name: Salford Royal NHS Foundation Trust , Salford – name: Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust , Stoke-on-Trent, UK – name: Karolinska Institute , Stockholm, Sweden – name: PortsmouthNHSTrust , Portsmouth, UK – name: Department of Surgery, University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK – name: Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge , Cambridge, UK – name: Department of Computer Science, University of Oxford , Oxford, UK – name: University Hospital Southampton NHS Foundation Trust , Southampton, UK – name: Department of Surgery, Royal Infirmary of Edinburgh , Edinburgh, UK – name: Department of Surgery, Nottingham University Hospitals NHS Trust , Nottingham, UK |
| Author_xml | – sequence: 1 givenname: F. surname: Noble fullname: Noble, F. organization: Cancer Sciences Unit, University of Southampton – sequence: 2 givenname: M. A. surname: Lloyd fullname: Lloyd, M. A. organization: Cancer Sciences Unit, University of Southampton – sequence: 3 givenname: R. surname: Turkington fullname: Turkington, R. organization: Centre for Cancer Research and Cell Biology, Queen's University Belfast – sequence: 4 givenname: E. surname: Griffiths fullname: Griffiths, E. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 5 givenname: M. surname: O'Donovan fullname: O'Donovan, M. organization: University of Cambridge – sequence: 6 givenname: J. R. surname: O'Neill fullname: O'Neill, J. R. organization: Royal Infirmary of Edinburgh – sequence: 7 givenname: S. surname: Mercer fullname: Mercer, S. organization: Portsmouth NHS Trust – sequence: 8 givenname: S. L. surname: Parsons fullname: Parsons, S. L. organization: Nottingham University Hospitals NHS Trust – sequence: 9 givenname: R. C. surname: Fitzgerald fullname: Fitzgerald, R. C. organization: University of Cambridge – sequence: 10 givenname: T. J. orcidid: 0000-0001-9455-2188 surname: Underwood fullname: Underwood, T. J. email: tju@soton.ac.uk organization: Cancer Sciences Unit, University of Southampton – sequence: 12 givenname: A. surname: Noorani fullname: Noorani, A. organization: University of Cambridge – sequence: 13 givenname: R. surname: Fels Elliott fullname: Fels Elliott, R. organization: University of Cambridge – sequence: 14 givenname: Z. surname: Abdullahi fullname: Abdullahi, Z. organization: University of Cambridge – sequence: 15 givenname: R. surname: de la Rue fullname: de la Rue, R. organization: University of Cambridge – sequence: 16 givenname: J. surname: Bornschein fullname: Bornschein, J. organization: University of Cambridge – sequence: 17 givenname: S. surname: MacRae fullname: MacRae, S. organization: University of Cambridge – sequence: 18 givenname: B. surname: Nutzinger fullname: Nutzinger, B. organization: University of Cambridge – sequence: 19 givenname: N. surname: Grehan fullname: Grehan, N. organization: University of Cambridge – sequence: 20 givenname: G. surname: Contino fullname: Contino, G. organization: University of Cambridge – sequence: 21 givenname: J. surname: Crawte fullname: Crawte, J. organization: University of Cambridge – sequence: 22 givenname: P. A. W. surname: Edwards fullname: Edwards, P. A. W. organization: University of Cambridge – sequence: 23 givenname: A. surname: Miremadi fullname: Miremadi, A. organization: Cambridge University Hospital NHS Trust – sequence: 24 givenname: S. surname: Malhotra fullname: Malhotra, S. organization: Cambridge University Hospital NHS Trust – sequence: 25 givenname: A. surname: Hayden fullname: Hayden, A. organization: University of Southampton – sequence: 26 givenname: R. surname: Walker fullname: Walker, R. organization: University of Southampton – sequence: 27 givenname: C. surname: Peters fullname: Peters, C. organization: Imperial College – sequence: 28 givenname: G. surname: Hannah fullname: Hannah, G. organization: Imperial College – sequence: 29 givenname: R. surname: Hardwick fullname: Hardwick, R. organization: Oesophago‐Gastric Unit, Addenbrooke's Hospital – sequence: 30 givenname: J. surname: Davies fullname: Davies, J. organization: Oxford ComLab, University of Oxford – sequence: 31 givenname: H. surname: Ford fullname: Ford, H. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 32 givenname: D. surname: Gilligan fullname: Gilligan, D. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 33 givenname: P. surname: Safranek fullname: Safranek, P. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 34 givenname: A. surname: Hindmarsh fullname: Hindmarsh, A. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 35 givenname: V. surname: Sujendran fullname: Sujendran, V. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 36 givenname: N. surname: Carroll fullname: Carroll, N. organization: Cambridge University Hospitals NHS Foundation Trust – sequence: 37 givenname: D. surname: McManus fullname: McManus, D. organization: Queen's University Belfast – sequence: 38 givenname: S. J. surname: Hayes fullname: Hayes, S. J. organization: University of Manchester – sequence: 39 givenname: Y. surname: Ang fullname: Ang, Y. organization: University of Cambridge – sequence: 40 givenname: S. R. surname: Preston fullname: Preston, S. R. organization: Royal Surrey County Hospital NHS Foundation Trust – sequence: 41 givenname: S. surname: Oakes fullname: Oakes, S. organization: Royal Surrey County Hospital NHS Foundation Trust – sequence: 42 givenname: I. surname: Bagwan fullname: Bagwan, I. organization: Royal Surrey County Hospital NHS Foundation Trust – sequence: 43 givenname: R. J. E. surname: Skipworth fullname: Skipworth, R. J. E. organization: Edinburgh Royal Infirmary – sequence: 44 givenname: V. surname: Save fullname: Save, V. organization: Edinburgh Royal Infirmary – sequence: 45 givenname: T. R. surname: Hupp fullname: Hupp, T. R. organization: Edinburgh University – sequence: 46 givenname: S. surname: Puig fullname: Puig, S. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 47 givenname: M. surname: Bedford fullname: Bedford, M. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 48 givenname: P. surname: Taniere fullname: Taniere, P. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 49 givenname: J. surname: Whiting fullname: Whiting, J. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 50 givenname: J. surname: Byrne fullname: Byrne, J. organization: University Hospital Southampton NHS Foundation Trust – sequence: 51 givenname: J. surname: Kelly fullname: Kelly, J. organization: University Hospital Southampton NHS Foundation Trust – sequence: 52 givenname: J. surname: Owsley fullname: Owsley, J. organization: University Hospital Southampton NHS Foundation Trust – sequence: 53 givenname: C. surname: Crichton fullname: Crichton, C. organization: University of Oxford – sequence: 54 givenname: H. surname: Barr fullname: Barr, H. organization: Gloucester Royal Hospital – sequence: 55 givenname: N. surname: Shepherd fullname: Shepherd, N. organization: Gloucester Royal Hospital – sequence: 56 givenname: O. surname: Old fullname: Old, O. organization: Gloucester Royal Hospital – sequence: 57 givenname: J. surname: Lagergren fullname: Lagergren, J. organization: Karolinska Institute – sequence: 58 givenname: J. surname: Gossage fullname: Gossage, J. organization: St Thomas's Hospital and King's College London – sequence: 59 givenname: A. surname: Davies fullname: Davies, A. organization: St Thomas's Hospital and King's College London – sequence: 60 givenname: F. surname: Chang fullname: Chang, F. organization: St Thomas's Hospital and King's College London – sequence: 61 givenname: J. surname: Zylstra fullname: Zylstra, J. organization: St Thomas's Hospital and King's College London – sequence: 62 givenname: G. surname: Sanders fullname: Sanders, G. organization: Plymouth Hospitals NHS Trust – sequence: 63 givenname: R. surname: Berrisford fullname: Berrisford, R. organization: Plymouth Hospitals NHS Trust – sequence: 64 givenname: C. surname: Harden fullname: Harden, C. organization: Plymouth Hospitals NHS Trust – sequence: 65 givenname: D. surname: Bunting fullname: Bunting, D. organization: Plymouth Hospitals NHS Trust – sequence: 66 givenname: M. surname: Lewis fullname: Lewis, M. organization: Norfolk and Norwich University Hospital NHS Foundation Trust – sequence: 67 givenname: E. surname: Cheong fullname: Cheong, E. organization: Norfolk and Norwich University Hospital NHS Foundation Trust – sequence: 68 givenname: B. surname: Kumar fullname: Kumar, B. organization: Norfolk and Norwich University Hospital NHS Foundation Trust – sequence: 69 givenname: J. H. surname: Saunders fullname: Saunders, J. H. organization: Nottingham University Hospitals NHS Trust – sequence: 70 givenname: I. N. surname: Soomro fullname: Soomro, I. N. organization: Nottingham University Hospitals NHS Trust – sequence: 71 givenname: R. surname: Vohra fullname: Vohra, R. organization: Nottingham University Hospitals NHS Trust – sequence: 72 givenname: J. surname: Duffy fullname: Duffy, J. organization: Nottingham University Hospitals NHS Trust – sequence: 73 givenname: P. surname: Kaye fullname: Kaye, P. organization: Nottingham University Hospitals NHS Trust – sequence: 74 givenname: A. surname: Grabowska fullname: Grabowska, A. organization: Nottingham University Hospitals NHS Trust – sequence: 75 givenname: L. surname: Lovat fullname: Lovat, L. organization: University College London – sequence: 76 givenname: R. surname: Haidry fullname: Haidry, R. organization: University College London – sequence: 77 givenname: V. surname: Eneh fullname: Eneh, V. organization: University College London – sequence: 78 givenname: L. surname: Igali fullname: Igali, L. organization: Norfolk and Waveney Cellular Pathology Network – sequence: 79 givenname: I. surname: Welch fullname: Welch, I. organization: Wythenshawe Hospital – sequence: 80 givenname: M. surname: Scott fullname: Scott, M. organization: Wythenshawe Hospital – sequence: 81 givenname: S. surname: Sothi fullname: Sothi, S. organization: University Hospitals Coventry and Warwickshire NHS Trust – sequence: 82 givenname: S. surname: Suortamo fullname: Suortamo, S. organization: University Hospitals Coventry and Warwickshire NHS Trust – sequence: 83 givenname: S. surname: Lishman fullname: Lishman, S. organization: Peterborough City Hospital, Peterborough Hospitals NHS Trust – sequence: 84 givenname: D. surname: Beardsmore fullname: Beardsmore, D. organization: Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust – sequence: 85 givenname: R. surname: Sutaria fullname: Sutaria, R. organization: PortsmouthNHSTrust – sequence: 86 givenname: M. surname: Secrier fullname: Secrier, M. organization: University of Cambridge – sequence: 87 givenname: M.D. surname: Eldridge fullname: Eldridge, M.D. organization: University of Cambridge – sequence: 88 givenname: L. surname: Bower fullname: Bower, L. organization: University of Cambridge – sequence: 89 givenname: A. G. surname: Lynch fullname: Lynch, A. G. organization: University of Cambridge – sequence: 90 givenname: S. surname: Tavaré fullname: Tavaré, S. organization: University of Cambridge |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28944954$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:137057781$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNpdks9u1DAQxi1URLeFAy-ALHHhEur4T5xckGgFBVTEAThbk3iyccjaIU622ofgnevuLhXl5E_-fjMafTNn5MQHj4S8zNnbnDF-UfcxiYLrJ2SVi0JlPC_KE7JijOksF1yckrMYe8ZywRR_Rk55WUlZKbkif74uw-wa9POEtAldmGYa58Xu6ByoxdZ5pOAt3cLgLMxIR5i7MIS1a2CgECPGuEnVNLR0wjgGH_G-1GMA2y9bSNbc4QTjjjpPA8YwdrAOa4jz5BoKFn1oYGqcDxt4Tp62MER8cXzPyc-PH35cfcpuvl1_vnp_k_VSC53VsuWy4U0pRM2YLbGQSkItdBI6BaJVZbmCsuVgVS1LbSWrJEhueV22Qohzkh36xlscl9qMk9vAtDMBnDl-_UoKjeaSK574dwc-ORu0-7hgeFT22PGuM-uwNUpzVegqNXhzbDCF3wvG2WxcbHAYIAW1RJNXkmsmSikT-vo_tA_L5FMciSrS2iotVKJe_TvRwyh_N5uAiwNw6wbcPfg5M_cnY9LJmP3JmMsv3_dC3AHrcLmX |
| ContentType | Journal Article |
| Contributor | Zylstra, J Duffy, J Crichton, C Kumar, B Skipworth, R J E Peters, C Carroll, N Taniere, P Cheong, E Lewis, M Lynch, A G Noorani, A Hardwick, R Sanders, G Bower, L Welch, I Old, O Beardsmore, D Sutaria, R Contino, G Sujendran, V Suortamo, S Lagergren, J Gossage, J Harden, C Saunders, J H Owsley, J Edwards, P A W Preston, S R Eneh, V Scott, M Abdullahi, Z Hupp, T R Igali, L de la Rue, R Miremadi, A Secrier, M Davies, A Ang, Y Bedford, M Gilligan, D Walker, R Chang, F Grehan, N Hayes, S J Barr, H Ford, H Whiting, J Kaye, P Oakes, S Tavaré, S Fels Elliott, R Bunting, D Nutzinger, B Davies, J Safranek, P Byrne, J Grabowska, A Haidry, R Vohra, R Eldridge, M D Hindmarsh, A Lovat, L Hayden, A Hannah, G Berrisford, R Bagwan, I Puig, S Crawte, J Lishman, S McManus, D Malhotra, S Kelly, J Sothi, S Bornschein, J Soomro, I N MacRae, S Save, V Shepherd, N |
| Contributor_xml | – sequence: 1 givenname: A surname: Noorani fullname: Noorani, A – sequence: 2 givenname: R surname: Fels Elliott fullname: Fels Elliott, R – sequence: 3 givenname: Z surname: Abdullahi fullname: Abdullahi, Z – sequence: 4 givenname: R surname: de la Rue fullname: de la Rue, R – sequence: 5 givenname: J surname: Bornschein fullname: Bornschein, J – sequence: 6 givenname: S surname: MacRae fullname: MacRae, S – sequence: 7 givenname: B surname: Nutzinger fullname: Nutzinger, B – sequence: 8 givenname: N surname: Grehan fullname: Grehan, N – sequence: 9 givenname: G surname: Contino fullname: Contino, G – sequence: 10 givenname: J surname: Crawte fullname: Crawte, J – sequence: 11 givenname: P A W surname: Edwards fullname: Edwards, P A W – sequence: 12 givenname: A surname: Miremadi fullname: Miremadi, A – sequence: 13 givenname: S surname: Malhotra fullname: Malhotra, S – sequence: 14 givenname: A surname: Hayden fullname: Hayden, A – sequence: 15 givenname: R surname: Walker fullname: Walker, R – sequence: 16 givenname: C surname: Peters fullname: Peters, C – sequence: 17 givenname: G surname: Hannah fullname: Hannah, G – sequence: 18 givenname: R surname: Hardwick fullname: Hardwick, R – sequence: 19 givenname: J surname: Davies fullname: Davies, J – sequence: 20 givenname: H surname: Ford fullname: Ford, H – sequence: 21 givenname: D surname: Gilligan fullname: Gilligan, D – sequence: 22 givenname: P surname: Safranek fullname: Safranek, P – sequence: 23 givenname: A surname: Hindmarsh fullname: Hindmarsh, A – sequence: 24 givenname: V surname: Sujendran fullname: Sujendran, V – sequence: 25 givenname: N surname: Carroll fullname: Carroll, N – sequence: 26 givenname: D surname: McManus fullname: McManus, D – sequence: 27 givenname: S J surname: Hayes fullname: Hayes, S J – sequence: 28 givenname: Y surname: Ang fullname: Ang, Y – sequence: 29 givenname: S R surname: Preston fullname: Preston, S R – sequence: 30 givenname: S surname: Oakes fullname: Oakes, S – sequence: 31 givenname: I surname: Bagwan fullname: Bagwan, I – sequence: 32 givenname: R J E surname: Skipworth fullname: Skipworth, R J E – sequence: 33 givenname: V surname: Save fullname: Save, V – sequence: 34 givenname: T R surname: Hupp fullname: Hupp, T R – sequence: 35 givenname: S surname: Puig fullname: Puig, S – sequence: 36 givenname: M surname: Bedford fullname: Bedford, M – sequence: 37 givenname: P surname: Taniere fullname: Taniere, P – sequence: 38 givenname: J surname: Whiting fullname: Whiting, J – sequence: 39 givenname: J surname: Byrne fullname: Byrne, J – sequence: 40 givenname: J surname: Kelly fullname: Kelly, J – sequence: 41 givenname: J surname: Owsley fullname: Owsley, J – sequence: 42 givenname: C surname: Crichton fullname: Crichton, C – sequence: 43 givenname: H surname: Barr fullname: Barr, H – sequence: 44 givenname: N surname: Shepherd fullname: Shepherd, N – sequence: 45 givenname: O surname: Old fullname: Old, O – sequence: 46 givenname: J surname: Lagergren fullname: Lagergren, J – sequence: 47 givenname: J surname: Gossage fullname: Gossage, J – sequence: 48 givenname: A surname: Davies fullname: Davies, A – sequence: 49 givenname: F surname: Chang fullname: Chang, F – sequence: 50 givenname: J surname: Zylstra fullname: Zylstra, J – sequence: 51 givenname: G surname: Sanders fullname: Sanders, G – sequence: 52 givenname: R surname: Berrisford fullname: Berrisford, R – sequence: 53 givenname: C surname: Harden fullname: Harden, C – sequence: 54 givenname: D surname: Bunting fullname: Bunting, D – sequence: 55 givenname: M surname: Lewis fullname: Lewis, M – sequence: 56 givenname: E surname: Cheong fullname: Cheong, E – sequence: 57 givenname: B surname: Kumar fullname: Kumar, B – sequence: 58 givenname: J H surname: Saunders fullname: Saunders, J H – sequence: 59 givenname: I N surname: Soomro fullname: Soomro, I N – sequence: 60 givenname: R surname: Vohra fullname: Vohra, R – sequence: 61 givenname: J surname: Duffy fullname: Duffy, J – sequence: 62 givenname: P surname: Kaye fullname: Kaye, P – sequence: 63 givenname: A surname: Grabowska fullname: Grabowska, A – sequence: 64 givenname: L surname: Lovat fullname: Lovat, L – sequence: 65 givenname: R surname: Haidry fullname: Haidry, R – sequence: 66 givenname: V surname: Eneh fullname: Eneh, V – sequence: 67 givenname: L surname: Igali fullname: Igali, L – sequence: 68 givenname: I surname: Welch fullname: Welch, I – sequence: 69 givenname: M surname: Scott fullname: Scott, M – sequence: 70 givenname: S surname: Sothi fullname: Sothi, S – sequence: 71 givenname: S surname: Suortamo fullname: Suortamo, S – sequence: 72 givenname: S surname: Lishman fullname: Lishman, S – sequence: 73 givenname: D surname: Beardsmore fullname: Beardsmore, D – sequence: 74 givenname: R surname: Sutaria fullname: Sutaria, R – sequence: 75 givenname: M surname: Secrier fullname: Secrier, M – sequence: 76 givenname: M D surname: Eldridge fullname: Eldridge, M D – sequence: 77 givenname: L surname: Bower fullname: Bower, L – sequence: 78 givenname: A G surname: Lynch fullname: Lynch, A G – sequence: 79 givenname: S surname: Tavaré fullname: Tavaré, S |
| Copyright | 2017 The Authors. published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. Copyright © 2017 BJS Society Ltd. Published by John Wiley & Sons, Ltd. 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. 2017 |
| Copyright_xml | – notice: 2017 The Authors. published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. – notice: 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. – notice: Copyright © 2017 BJS Society Ltd. Published by John Wiley & Sons, Ltd. – notice: 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. 2017 |
| CorporateAuthor | OCCAMS consortium |
| CorporateAuthor_xml | – name: OCCAMS consortium |
| DBID | 24P CGR CUY CVF ECM EIF NPM K9. 7X8 5PM ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1002/bjs.10627 |
| DatabaseName | Wiley-Blackwell Open Access Titles Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1365-2168 |
| EndPage | 1828 |
| ExternalDocumentID | oai_swepub_ki_se_724252 PMC5725679 28944954 BJS10627 |
| Genre | article Multicenter Study Journal Article |
| GrantInformation_xml | – fundername: Cancer Research UK (Clinical Lectureship) funderid: RG84119 – fundername: Medical Research Council Clinician Scientist Fellowship funderid: G1002565 – fundername: Experimental Cancer Medicine Centre – fundername: National Institute for Health Research Cambridge Biomedical Research Centre – fundername: Cancer Research UK grantid: 20406 – fundername: Medical Research Council grantid: G1002565 – fundername: Cancer Research UK grantid: 23924 – fundername: ; grantid: RG84119 – fundername: ; – fundername: ; grantid: G1002565 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OC 1ZS 23N 24P 31~ 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 5WD 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AABZA AACZT AAESR AAEVG AAGQS AAMMB AANHP AAONW AAPGJ AAPXW AAQQT AARHZ AAUAY AAVAP AAWDT AAYEP AAZKR ABCQN ABCUV ABDFA ABEJV ABEML ABGNP ABIJN ABJNI ABLJU ABNHQ ABOCM ABPQP ABPTD ABPVW ABQNK ABVGC ABWST ABXVV ACBWZ ACFBH ACFRR ACGFO ACGFS ACMXC ACPOU ACRPL ACSCC ACUTJ ACVCV ACXQS ACYHN ACYXJ ACZBC ADBBV ADEOM ADIPN ADIYS ADIZJ ADKYN ADMGS ADMTO ADNBA ADNMO ADQBN ADVEK ADXAS ADZMN AEFGJ AEGXH AEIMD AEMQT AENEX AFBPY AFFNX AFFQV AFFZL AFGKR AFXAL AFYAG AFYLJ AFZJQ AGMDO AGQPQ AGQXC AGUTN AGXDD AHGBF AHMBA AHMMS AI. AIAGR AIDQK AIDYY AIURR AJAOE AJBYB AJDVS AJEEA AJNCP ALAGY ALMA_UNASSIGNED_HOLDINGS ALXQX AMBMR AMYDB APJGH AQDSO ASPBG ATGXG ATUGU AVNTJ AVWKF AZBYB AZFZN AZVAB BAFTC BCRHZ BDRZF BEYMZ BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FLUFQ FOEOM FUBAC G-S G.N GNP GODZA H.X H13 HBH HF~ HHY HHZ HVGLF HZ~ IH2 IHE IX1 J0M J5H JPC JXSIZ KBUDW KOP KQQ KSI KSN L7B LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NOMLY NU- O66 O9- OAUYM OBFPC OCZFY OHH OIG OJZSN OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL ROX RX1 RYL SUPJJ TEORI TMA UB1 V2E V8K V9Y VH1 VVN W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI X7M XG1 XV2 YFH YOC YUY ZGI ZXP ZY1 ZZTAW ~IA ~WT AGORE CGR CUY CVF ECM EIF NPM RIG K9. O8X 7X8 5PM ADTPV ALUQN AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-j4737-b4f24c2c833b00d8e6454ab37e647002759d25a8f2ad5b487d4094a42d2b8f333 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 90 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000415360000009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-1323 1365-2168 |
| IngestDate | Tue Nov 25 03:33:32 EST 2025 Tue Sep 30 15:48:08 EDT 2025 Sat Sep 27 17:00:39 EDT 2025 Sat Nov 29 14:38:02 EST 2025 Mon Jul 21 06:04:03 EDT 2025 Sun Sep 21 06:18:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| License | Attribution 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-j4737-b4f24c2c833b00d8e6454ab37e647002759d25a8f2ad5b487d4094a42d2b8f333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Members of the OCCAMS consortium are co-authors of this article and can be found under the heading Collaborators. |
| ORCID | 0000-0001-9455-2188 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbjs.10627 |
| PMID | 28944954 |
| PQID | 1964499735 |
| PQPubID | 976337 |
| PageCount | 13 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_724252 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5725679 proquest_miscellaneous_1942703844 proquest_journals_1964499735 pubmed_primary_28944954 wiley_primary_10_1002_bjs_10627_BJS10627 |
| PublicationCentury | 2000 |
| PublicationDate | December 2017 |
| PublicationDateYYYYMMDD | 2017-12-01 |
| PublicationDate_xml | – month: 12 year: 2017 text: December 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | Chichester, UK |
| PublicationPlace_xml | – name: Chichester, UK – name: England – name: Oxford |
| PublicationTitle | British journal of surgery |
| PublicationTitleAlternate | Br J Surg |
| PublicationYear | 2017 |
| Publisher | John Wiley & Sons, Ltd Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Ltd – name: Oxford University Press |
| References | 2001; 91 2009; 22 2010; 97 2010; 17 2011; 60 2007; 141 2015; 33 2010; 102 1998; 339 2002; 359 2009 2008; 15 2006; 19 2014; 46 2011; 12 2008; 2 2017; 115 2016; 34 2006; 355 2013; 19 2006; 82 2009; 55 2009; 54 2005; 242 2011; 92 2013; 258 2003; 24 2006; 106 2016; 48 2007; 25 1994; 73 2014; 32 2001; 54 |
| References_xml | – year: 2009 – volume: 258 start-page: 784 year: 2013 end-page: 792 article-title: Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3‐point standard publication-title: Ann Surg – volume: 22 start-page: 1555 year: 2009 end-page: 1563 article-title: Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas publication-title: Mod Pathol – volume: 97 start-page: 719 year: 2010 end-page: 725 article-title: Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci publication-title: Br J Surg – volume: 24 start-page: 631 year: 2003 end-page: 636 article-title: Tumor response to induction chemoradiation: influence on survival after esophagectomy publication-title: Eur J Cardiothorac Surg – volume: 60 start-page: 1449 year: 2011 end-page: 1472 article-title: Guidelines for the management of oesophageal and gastric cancer publication-title: Gut – volume: 17 start-page: 1159 year: 2010 end-page: 1167 article-title: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer publication-title: Ann Surg Oncol – volume: 73 start-page: 2680 year: 1994 end-page: 2686 article-title: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations publication-title: Cancer – volume: 48 start-page: 1131 year: 2016 end-page: 1141 article-title: Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance publication-title: Nat Genet – volume: 19 start-page: 9282 year: 2013 end-page: 9293 article-title: Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus publication-title: World J Gastroenterol – volume: 34 start-page: 2721 year: 2016 end-page: 2727 article-title: Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial publication-title: J Clin Oncol – volume: 359 start-page: 1727 year: 2002 end-page: 1733 article-title: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial publication-title: Lancet – volume: 32 start-page: 2983 year: 2014 end-page: 2990 article-title: Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction publication-title: J Clin Oncol – volume: 46 start-page: 837 year: 2014 end-page: 843 article-title: OCCAMS Consortium. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis publication-title: Nat Genet – volume: 141 start-page: 570 year: 2007 end-page: 580 article-title: The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus publication-title: Surgery – volume: 54 start-page: 841 year: 2001 end-page: 845 article-title: A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy publication-title: J Clin Pathol – volume: 106 start-page: 2119 year: 2006 end-page: 2127 article-title: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas publication-title: Cancer – volume: 54 start-page: 713 year: 2009 end-page: 721 article-title: Rectal cancer staging post neoadjuvant therapy – how should the changes be assessed? publication-title: Histopathology – volume: 102 start-page: 1600 year: 2010 end-page: 1607 article-title: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro‐oesophageal cancer treated with neoadjuvant chemotherapy publication-title: Br J Cancer – volume: 12 start-page: 681 year: 2011 end-page: 692 article-title: Australasian Gastro‐Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis publication-title: Lancet Oncol – volume: 19 start-page: 329 year: 2006 end-page: 334 article-title: Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use? publication-title: Dis Esophagus – volume: 22 start-page: 291 year: 2009 end-page: 297 article-title: Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis publication-title: Dis Esophagus – volume: 55 start-page: 399 year: 2009 end-page: 406 article-title: Tumour regression grade (TRG) analyses in patients with resectable gastro‐oesophageal adenocarcinomas treated with platinum‐based neoadjuvant chemotherapy publication-title: Histopathology – volume: 91 start-page: 2165 year: 2001 end-page: 2174 article-title: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy surgery alone publication-title: Cancer – volume: 15 start-page: 2894 year: 2008 end-page: 2902 article-title: Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response publication-title: Ann Surg Oncol – volume: 242 start-page: 684 year: 2005 end-page: 692 article-title: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification publication-title: Ann Surg – volume: 33 issue: Suppl year: 2015 article-title: Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072) publication-title: J Clin Oncol – volume: 2 start-page: 287 year: 2008 end-page: 294 article-title: The value of PET imaging in patients with localized gastroesophageal cancer publication-title: Gastrointest Cancer Res – volume: 115 start-page: 821 year: 2017 end-page: 829 article-title: The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery publication-title: J Surg Oncol – volume: 82 start-page: 480 year: 2006 end-page: 484 article-title: Downstaging of T or N predicts long‐term survival after preoperative chemotherapy and radical resection for esophageal carcinoma publication-title: Ann Thorac Surg – volume: 25 start-page: 3719 year: 2007 end-page: 3725 article-title: Radiation Therapy Oncology Group; USA Intergroup. Long‐term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer publication-title: J Clin Oncol – volume: 92 start-page: 2020 year: 2011 end-page: 2027 article-title: Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer publication-title: Ann Thorac Surg – volume: 355 start-page: 11 year: 2006 end-page: 20 article-title: MAGIC Trial Participants. Perioperative chemotherapy surgery alone for resectable gastroesophageal cancer publication-title: N Engl J Med – volume: 339 start-page: 1979 year: 1998 end-page: 1984 article-title: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer publication-title: N Engl J Med |
| SSID | ssj0013052 |
| Score | 2.5321405 |
| Snippet | Background
This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in... This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal... BackgroundThis multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in... Response associated with survival |
| SourceID | swepub pubmedcentral proquest pubmed wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1816 |
| SubjectTerms | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Chemotherapy Chemotherapy, Adjuvant Cisplatin - administration & dosage Cohort analysis Cohort Studies Digital divide Epirubicin - administration & dosage Esophageal cancer Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Female Fluorouracil - administration & dosage Humans Lymph Nodes - pathology Lymphatic Metastasis - pathology Lymphatic system Male Middle Aged Neoadjuvant Therapy Neoplasm Grading Neoplasm Staging Original Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - therapy Toxicity |
| Title | Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbjs.10627 https://www.ncbi.nlm.nih.gov/pubmed/28944954 https://www.proquest.com/docview/1964499735 https://www.proquest.com/docview/1942703844 https://pubmed.ncbi.nlm.nih.gov/PMC5725679 http://kipublications.ki.se/Default.aspx?queryparsed=id:137057781 |
| Volume | 104 |
| WOSCitedRecordID | wos000415360000009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2168 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013052 issn: 0007-1323 databaseCode: DRFUL dateStart: 19980101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VlgMXCuIVKJWREOISdWM7taOeymOFEKoqoNLeIjt22iwiQdksEj-C_9wZO5tqBQckLtEoHiuO5uEZP74BeJmFWTUzaS38cUoBb2qkLdLCZobL3KrcylBsQp2d6cWiON-Bk81dmIgPMS24kWUEf00Gbuzq6AY01C5XSB5zdQv2skxoqtvA5fnNFsIsj1DhhIIouNjACs340dT1b2Hln6cjRwzR7fA1zD_z_f8a-T24O4ad7DTqyX3Y8e0D-B1u34YBeEaVcvuBBbhZNnTM-Ro_xEzrGCpjQwsDjMoXb5wlMxOmJ-tq1seztp66tr4zbrnGGH1g8X7XL9a0rPNUMsFcdpeGioVUzKDPw6m0r5q2-24ewsX8_de3H9KxPEO6lEqo1Mqay4pXWgi0Xac9gYMZKxQSitLdvHA8N7rmxqHEtXKUSxrJHbe6FkI8gt22a_0TYFZlWaUx0OdeSTvz2mS-dg5zwaygreQEDjZyKkcbW5UEJYb5mhJ5Ai-mZrQO2vIw-Ktr4pEcfZqWMoHHUazljwjjUWKqif1zbFFbAp8YCHl7u6VtrgICd64wUlRFAq-iamx1GV99Q8qXilI6nsDroBATXwSL5iWqQhlUoXzz8Usgnv476zO4wynICIdrDmB36Nf-Odyufg7Nqj8M1oBPtdCHsPfu8_zi0zX8fRQ0 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB9qFfTFKn40WnUFEV9CL7ubbgK-VLFUrUfBCn1bdrObmismkssJ_hH-z87s5lIOfRB8G7IzJGHncz9-A_AiC1E1M2kt_EFKCW9qpC3T0maGy9yq3MrQbELN58X5eXm6Ba_Xd2EiPsS04EaWEfw1GTgtSO9foYbaxRLJA66uwXWJUYa0nMvTqz2EWR6xwgkGUXCxxhWa8f1J9G955Z_HI0cQ0c38NQSgo53_-_Q7cHtMPNlh1JS7sOXbe_Ar3L8NX-AZ9crtBxYAZ9nQMedrfBMzrWOojg0tDTBqYLx2l8xMqJ6sq1kfT9t6Em19Z9xihVn6wOINr5-saVnnqWmCueguDLULqZhBr4fBtK-atvtm7sOXo3dnb4_TsUFDupBKqNTKmsuKV4UQaL2u8AQPZqxQSCgqePPS8dwUNTcO57xQjqpJI7njtqiFEA9gu-1avwvMqiyrCkz1uVfSznxhMl87h9VgVtJmcgJ764nSo5UtNYGJYcWmRJ7A82kY7YM2PQz-6op4JEevVkiZwMM4r_p7BPLQWGyifI4jamPGJwbC3t4caZuvAYM7V5grqjKBl1E3NkTGR5dIea2oqOMJvAoaMfFFuGiuURV0UAX95sPnQDz6d9ZncPP47NOJPnk___gYbnFKOcJRmz3YHvqVfwI3qh9Ds-yfBtP4DTDIFZc |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_qVcQXq6g1WnUFEV9CL7ub7gZ86YeHH-UoaqFvYTe7qTkxKbmc4B_h_-zMJpdy6IPg25CdIQnzsTP78RuAl0mYVRMTl8IfxJTwxkbaLM5sYrhMrUqtDM0m1HyuLy6ysy14s74L0-NDjAtu5BkhXpOD-ytX7l-jhtrFEskDrm7AtqQmMhPYPvk0Oz-93kWYpj1aOAEhCi7WyEJTvj8K_y2z_POA5AAjupnBhilotvN_H38X7gypJzvsbeUebPn6PvwKN3DDF3hG3XLbjgXIWdY1zPkS38RM7RgaZEWLA4xaGK8DJjMjridrStb25209ida-MW6xwjy9Y_0dr5-sqlnjqW2CuWwuDTUMKZjBuIfTaVtUdfPdPIDz2dsvx-_ioUVDvJBKqNjKksuCF1oI9F-nPQGEGSsUEopK3jRzPDW65Mah1rVyVE8ayR23uhRCPIRJ3dT-ETCrkqTQmOxzr6Sdem0SXzqH9WCS0XZyBHtrReWDny1zghPDmk2JNIIX4zB6CG17GPzVFfFIjnFNSxnBbq_X_KqH8six3ET5FEfUhsZHBkLf3hypq68BhTtVmC2qLIJXvW1siAyPviHlc0VlHY_gdbCIka8HjOY5mkIeTCE_-vA5EI__nfU53Do7meWn7-cfn8BtTjlHOGuzB5OuXfmncLP40VXL9tngG78BnjAWrQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicentre+cohort+study+to+define+and+validate+pathological+assessment+of+response+to+neoadjuvant+therapy+in+oesophagogastric+adenocarcinoma&rft.jtitle=British+journal+of+surgery&rft.au=Noble%2C+F&rft.au=Lloyd%2C+MA&rft.au=Turkington%2C+R&rft.au=Griffiths%2C+E&rft.date=2017-12-01&rft.issn=0007-1323&rft.volume=104&rft.issue=13&rft.spage=1816&rft_id=info:doi/10.1002%2Fbjs.10627&rft.externalDocID=oai_swepub_ki_se_724252 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1323&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1323&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1323&client=summon |